Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Chimerix: Thinking on the Stock in the Aftermath of Results from the AdVise Trial (CMRX, $4.95)

Overview

In a report published on April 14th I recommended purchasing Chimerix at a†price of $5.67. The catalyst for my recommendation…
Read more…

Chimerix: An Intriguing Near Term and Long Term Outlook for the Stock (CMRX, Buy, $5.67)

Investment Thesis in Brief
I am recommending purchase of Chimerix at the current price. The failure of brincidofovir in the phase…
Read more…

Chimerix: Upgrading the Stock to a Buy (CMRX. Buy, $6.10)

Definitions of Key Words

This section defines a number of words, phrases and acronyms that I have used in this report…
Read more…

Chimerix: An Update (CMRX, $52.83, Neutral)

Company Description

Chimerix is focused on the development and commercialization of antiviral drugs. Its lead product brincidofovir is a phospholipid derivative…
Read more…

SmithOnStocks Mailbox, January 31 Edition: My Take on News Events Relating to Companies I Follow

Introduction

A number of subscribers have suggested that I write more on recent news events that relate to companies that I…
Read more…

Chimerix: A Review of Recent Analyst Day Presentations with a Focus on Adenovirus and Ebola (CMRX, $31.31, Neutral)

The fundamental outlook for Chimerix is very attractive in my opinion. My model suggests that sales of its lead drug…
Read more…

Chimerix: Moving to a Buy (CMRX, $14.22, Paid subscribers)

Investment Thesis

I wrote a major report on Chimerix on March 13, 2014. I had been working on the report for…
Read more…

Thoughts on the Market Correction in Biotechnology Stocks

This Has Been a Tough Correction

The recent sharp market correction and rotation out of growth stocks like biotechnology and technology…
Read more…

Chimerix is A Company Focused on Infectious Viral Diseases that Has Investment Characteristics Similar to Trius (CMRX, Neutral, $25.48) (Subscribers Only)

Report In Brief
This report is an in-depth analysis of Chimerix (CMRX). I like the fundamental outlook of this company very…
Read more…

The BIO CEO Conference: Highlights from the Meeting and New Investment Perspectives (Subscribers Only)

Back From BIO CEO Conference

I have returned from spending two days at the BIO CEO conference at the Waldorf Astoria…
Read more…